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ABSTRACT: ONC201 is a first-in-class imipridone molecule
currently in clinical trials for the treatment of multiple cancers.
Despite enormous clinical potential, the mechanism of action is
controversial. To investigate the mechanism of ONC201 and
identify compounds with improved potency, we tested a series of
novel ONC201 analogues (TR compounds) for effects on cell
viability and stress responses in breast and other cancer models. The
TR compounds were found to be ∼50−100 times more potent at
inhibiting cell proliferation and inducing the integrated stress
response protein ATF4 than ONC201. Using immobilized TR
compounds, we identified the human mitochondrial caseinolytic
protease P (ClpP) as a specific binding protein by mass spectrometry. Affinity chromatography/drug competition assays showed
that the TR compounds bound ClpP with ∼10-fold higher affinity compared to ONC201. Importantly, we found that the
peptidase activity of recombinant ClpP was strongly activated by ONC201 and the TR compounds in a dose- and time-
dependent manner with the TR compounds displaying a ∼10−100 fold increase in potency over ONC201. Finally, siRNA
knockdown of ClpP in SUM159 cells reduced the response to ONC201 and the TR compounds, including induction of CHOP,
loss of the mitochondrial proteins (TFAM, TUFM), and the cytostatic effects of these compounds. Thus, we report that ClpP
directly binds ONC201 and the related TR compounds and is an important biological target for this class of molecules.
Moreover, these studies provide, for the first time, a biochemical basis for the difference in efficacy between ONC201 and the
TR compounds.
ONC201 (also known as TIC10) was originally identifiedfrom an NCI chemical library screen for its ability to
induce TRAIL (tumor necrosis factor-alpha-related apoptosis-
inducing ligand) gene transcription in a human colon cancer
cell line (HCT116).1 ONC201 has shown growth inhibitory
effects in multiple cancer cell lines and antitumor activity in
animal models of glioblastoma, colorectal, non-Hodgkins
lymphoma, and pancreatic cancer (reviewed in ref 2). As a
result of these promising preclinical studies, its drug-like
properties, its low toxicity in animals, and its penetration of the
blood−brain barrier, ONC201 has rapidly advanced and is
currently in 15 clinical trials (ClinicalTrials.gov identifier:
NCT02863991).2,3 In 2018, ONC201 was granted Fast Track
Designation for the treatment of adult recurrent H3 K27 M
mutant high-grade gliomas.
Despite significant preclinical promise,3−5 no defined
mechanism of action for ONC201 has been established.
While TRAIL was found to be induced by ONC201 in some
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cell types,1,6 this was not consistently observed in all studies.
Specifically, TRAIL was not increased in breast cancer cell lines
even though ONC201 strongly reduced cell viability.7
ONC201 was also effective against TRAIL-resistant breast
cancer cells8 and hematological malignancies independently of
TRAIL.9 Although ONC201 has been reported to increase the
DR5 death receptor,2 Greer et al. did not observe increased
DR4 or DR5 expression after ONC201 treatment, nor did
knockdown of DR4 or DR5 affect the inhibitory activity of
ONC201.7
ONC201 has been reported to inhibit Akt and ERK activity,
potentially providing a mechanism to explain TRAIL induction
through FOX3a.2,10,11 Again, this was not observed by others
despite significant effects of ONC201 on cell growth.7 Finally,
it was also reported that the dopamine receptors (DRD2 and
DRD3) may be targets of ONC201.12 However, direct
evidence for this interaction has been sparse, and siRNA-
mediated knockdown of these receptors did not reduce
ONC201’s inhibitory effect.12
Recently, ONC201 was shown to kill breast cancer cells by
targeting mitochondria and mitochondrial metabolism.7
Consistent with multiple previous reports,2 Lipkowitz and
colleagues reported that ONC201 induced an integrated stress
response (ISR) as shown by the induction of ATF4 and the C/
EBP homology protein (CHOP).7,13 Although a specific
mechanism was not elucidated, there was a direct correlation
observed between the antiproliferative activity of ONC201,
reduced oxidative phosphorylation, and the number of viable
mitochondria. Moreover, ONC201 was shown to be ineffective
in Rho0 cells (cells with impaired mitochondrial function due
to chemical depletion of mitochondrial DNA).7
Taken together, these studies indicated the necessity to
investigate and identify the potential targets for ONC201 and
related compounds. The SAR of the ONC201 chemical series
has been investigated though an iterative process of chemical
optimization and subsequent testing in cell viability assays.11
Importantly, the initial chemical structure for the compound
was determined to be incorrect by Janda and colleagues,14
spurring a series of synthetic efforts leading to the
identification of novel chemical entities based on this newly
discovered pharmacophore.15 Madera Therapeutics created a
series of novel highly potent analogues of ONC201 and
defined a new chemical series collectively known as TR
compounds.16−18 To investigate potential targets for ONC201
and the related TR compounds, we applied an unbiased affinity
proteomics approach to identify potential targets. In this study,
we report human mitochondrial ClpP as a key protein that
binds ONC201 and related compounds in a direct and specific
manner. In addition, we show that pretreatment of isolated
recombinant ClpP with ONC201 and the TR compounds
significantly increases the activity of ClpP. We show that ClpP
activation by ONC201 and related compounds in vitro
correlates directly with their biological potency in cells. Finally,
we demonstrate that these compounds act through ClpP
activation to induce the ISR, inhibition of protein synthesis,
and mitochondrial events related to inhibition of cell growth.
■ METHODS
Chemical Compounds. ONC201 was obtained from Sell-
eckChem (S7963). The TR compounds and D9 were supplied by
Madera Therapeutics, LLC and Nanjing Gator Meditech, Ltd. ADEP
was obtained from Cayman Chemical (A-54556A). All compounds
were dissolved in DMSO unless otherwise stated.
Cell Culture. Human Triple Negative Breast Cancer (TNBC) cell
lines SUM159 and MDA-MB-231 were a generous gift from Dr. Gary
Johnson at UNC CH. SUM159 cells were cultured in Dulbecco’s
modified Eagle’s medium: Nutrient Mixture F-12 (DMEM/F12,
0565-018, Thermo Fisher Scientific) supplemented with 5% fetal
bovine serum (FBS, TMS-013-B, Millipore), 5 μg/mL insulin, 1 μg/
mL hydrocortisone, and 1% mixture of antibiotic−antimycotic
(15240062, Thermo Fisher Scientific). MDA-MB-231 cells were
cultured in RPMI 1640 media (11875-093, Thermo Fisher Scientific)
supplemented with 10% FBS and 1% antibiotic−antimycotic. Cells
were incubated at 5% CO2 and 37°C. HeLa, A549, Panc1, PC3, and
MCF-7 cells were obtained from ATCC and maintained in DMEM
with 10% FBS and 1% antibiotic.
Viability Assays. Resazurin Assay. Cell viability assays were
performed by plating SUM159 (1000 cells/well) on a Cellstar 96-well
plate (655-180, Griener) in supplemented DMEM:F12 and allowed
to incubate/adhere overnight. After adherence, the media in each well
was aspirated and replaced with 50 μL of pure media and 50 μL of
media containing the drug at twice the final concentration. The
concentrations of drugs used are shown in the figure legends and
discussed in the text. Cells treated with DMSO (vehicle only) were
used as a negative control in all experiments. The final concentration
of DMSO (vehicle) was kept under 1% in all experiments.
Cells treated with appropriate concentrations of selected
compounds for 72 h in 100 μL of incubation media were
supplemented with 20 μL of resazurin (0.6 mM, Acros Organics
62758-13-8) and incubated for 30 min at 37°C. Cells were incubated
to allow metabolism to resorufin, at which point 75 μL of each sample
was transferred to a Costar black 96-well plate (CLS3915, Millipore
Sigma), and the relative fluorescence of resorufin across samples was
determined using a PHERAstar (BMG Labtech) with fluorescent
module FI: 540-20, 590-20. The results were analyzed using
GraphPad Prism 7 software which was used to generate the dose-
dependence curves and to calculate IC50 values.
Total Cell Counting. Total cell counting assays were performed by
plating SUM159 (50 cells/well) on a 96-well Greiner plate in
supplemented DMEM:F12, allowing them to incubate/adhere
overnight, and treating with drug as described above. At a
predetermined time point (0, 24, 48, or 72 h), media was aspirated,
and 100 μL of Hoechst stain (1 μg/mL, H3570, Thermo Fisher
Scientific) was added to each well and then allowed to incubate for 30
min at 37 °C. Total cell number was then quantified using the Celigo
Imaging Cytometer (Nexcelom).
Crystal Violet Assays. Crystal violet assays were performed by
plating SUM159 (1000 cells/well) on a 6-well Costar plate
(CLS3506, Millipore Sigma) and allowing them to incubate/adhere
overnight. Media was aspirated and replaced by media containing the
drug at the desired concentration. Cells were allowed to incubate for
48 h, and the media was either replaced by fresh media with drug or
media without drug. Cells were then allowed to incubate until one
well was 100% confluent, changing media as needed. Once confluent,
cells were stained using 0.5% crystal violet in 20% methanol, allowed
to incubate for 10 min at RT, then rinsed 3 times and allowed to dry
overnight. Staining was quantified by dissolving crystal violet stain in
Sorenson’s buffer (0.1 M sodium citrate, 50% ethanol, pH 4.2) and
measuring the absorption of dissolved crystal violet at 570 nm using a
BMG Polarstar Omega.
Immunoblotting. For Western blotting, SUM159 or MDA-MB-
231 cells were plated and treated with compounds as described above
for cell viability assays. Following treatment, cells were rinsed 3 times
with 2 mL of cold PBS and lysed using RIPA buffer (no SDS)
supplemented with 2 mM Na(VO3)4, 10 mM NaF, 0.0125 μM
calyculin A, and complete protease inhibitor cocktail (11873580001,
Roche Diagnostics). Cell lysates were clarified and immunoblotted as
described earlier.19 Membranes were incubated with the following
primary antibodies: [TUFM (PA5-27511), IDH2 (PA5-79436) from
Invitrogen]; [ClpP (CS-14181), ATF4 (CS-11815), LONP (CS-
28020), Aconitase (CS-6922s) from Cell Signaling Technologies]; [β-
actin (SC-47778), CHOP (SC-575), TFAM, (SC-376672), ClpP
(SC-271284) from Santa Cruz Biotechnologies] diluted 1:1000 in 5%
TBST/BSA + 0.02% NaN3) overnight at 4°C, removed, washed 3 × 5
min in TBST, and placed in their respective 2° antibodies (1:10 000
dilution in 5% milk/TBST) for 1 h. Membranes washed 3 × 5 min in
TBST were embedded in 2 mL of each ECL reagent and imaged
using a Chemidoc MP (BioRad) or developed with film. Acquired
images were processed/quantified using Image Lab software
(BioRad).
Reverse Transfection. All siRNA stocks were ordered from
Dharmacon at 2 nmol/siRNA and resuspended in 100 μL 1× siRNA
reconstitution buffer (Dharmacon) to create a 20 μM stock.
Dharmafect I was diluted 1:266 in OptiMEM media and divided
into 250 μL aliquots. Individual siRNAs were added to Dharmafect
aliquots for a final concentration of 125 nM, incubated at RT for 30
min, and then added to 6-well or 96-well plates. SUM159 cells were
washed with PBS and trypsinized at 37 °C for 5 min. Cells were
resuspended to a final concentration of 1 × 105 cells/mL (6-well) or 1
× 104 cells/mL (96-well) in 1:1 DMEM:F-12 supplemented with 5%
FBS, 5 μg/mL insulin, and 1 μg/mL hydrocortisone. Cells (1.0 mL/
well, 100 μL/well) were added to each well containing siRNA and
incubated for 24 h.
Caspase and Apoptosis Assays. Caspase 3/7 activity was
analyzed using a fluorescent peptide substrate (7-amido-4-methyl-
coumarin).19 The cells were plated at 8 × 105 cells per plate (6 cm
plate) and treated for 24 h with 3, 30, and 300 nM TR57 and TR31;
300 nM, 3 μM, and 30 μM ONC201, as well as 0.1% DMSO and 10
nM staurosporine (IC25 on SUM159 cells determined by MTS cell
viability assay (data not shown)). The samples were harvested by
mechanical scraping of the cells into 400 μL of lysis buffer (50 mM
HEPES (pH: 7.4), 5 mM CHAPS, and 5 mM DTT), and caspase
activity was measured as described earlier.19
Affinity Capture of Protein Targets. To generate TR-80 or TR-
81 affinity resins, we coupled free TR-80 or TR-81 to NHS-activated
agarose (Thermo Scientific catalog #26200). Briefly, NHS-agarose
beads were allowed to react with TR-80 or TR-81 at a final
concentration of 5 mM in coupling buffer (PBS with 20% DMSO) for
4 h at RT. Following washing with PBS to remove unbound ligand,
the beads were blocked for an additional hour with 1 M Tris-HCl, pH
7.5. Control agarose beads were generated by blocking uncoupled
NHS-agarose beads with 1 M Tris-HCl, pH 7.5. Primaquine (PQ)-
agarose was generated by coupling NHS-agarose with 20 mM
primaquine in phosphate buffered saline, pH 8.0.
To identify TR-80 interacting proteins, approximately 50 × 106
HeLa cells were homogenized in cell lysis buffer (50 mM Tris-HCl,
pH 7.5, 150 mM NaCl, 2 mM EDTA, 0.5% NP-40) and clarified by
centrifugation (15 min at 13 000g). The resultant supernatant was
divided into 1 mL aliquots and mixed with ∼50 μL packed beads of
control agarose, PQ-agarose, or TR-80 agarose in the presence of 2%
DMSO or 1.25 mM free TR-80 and rotated for one h at RT. Beads
were then collected by centrifugation and washed 3 times, 1 mL each
wash, with cell lysis buffer. Beads were boiled in SDS sample buffer,
resolved by SDS-PAGE using 11% polyacrylamide gels, and silver
stained as described.20 A protein band, indicated by the arrow, was
excised, destained, trypsin digested, and subjected to mass
spectrometry for identification (see below).
TR-81 Elution. To determine the specificity of protein interactions
with TR-81 beads, ∼ 30 μL of TR-81 agarose was mixed with 1 mL of
HeLa cell lysate generated as described above. After washing the
beads to remove nonspecific interactions, the beads were incubated
with 100 μL of elution buffer (50 mM Tris-HCl, pH 7.5, 150 mM
NaCl) containing 2% DMSO or 50 μM TR-57 for 30 min at RT. The
eluant was collected, resolved on an 11% polyacrylamide gel and silver
stained or immunoblotted with ClpP antibodies.
In Vitro Drug Competition Assays. To compare the relative
binding ability of different compounds to ClpP, ∼200−400 μL of
HeLa cell lysate (generated as described above) was mixed with
vehicle (2% DMSO final) or different concentrations of ONC201 or
TR compounds. After mixing for 15 min, the lysate was combined
with ∼20 μL packed TR-80 beads and rotated for 1 h at RT. The
supernatant was discarded, and beads were washed briefly 3 times, 1
mL each wash, with cell lysis buffer before boiling in SDS sample
buffer. Samples were then resolved by SDS-PAGE and immuno-
blotted with ClpP antibodies. To compare the ability of the
compounds to compete for ClpP binding within live cells, HeLa
cells in culture were treated with DMSO (final concentration 0.1%) or
various concentrations of ONC201 or TR compounds for 30 min.
Cells were then snap frozen, and lysates were subsequently prepared
and analyzed in a similar manner as described above.
MALDI TOF/TOF Analysis. The resultant tryptic peptides
obtained from the silver stained band were desalted using a C18
Zip-Tip and applied to a MALDI target plate with α-cyano-4-
hydroxycinnamic acid as the matrix. The sample was analyzed on an
AB Sciex 5800 MALDI TOF/TOF mass spectrometer. MS/MS
spectra were searched against a Uniprot human database using
Mascot version 2.3 (Matrix Science) within ProteinPilot software
version 3.0 (AB Sciex). A significance score threshold was calculated
in Mascot, and an ion score above 36 was considered a significant
identification (p < 0.05).
Measurement of Human ClpP Activity. Measurement of in
vitro activity of recombinant human caseinolytic peptidase ClpP (Cat
# MBS204060, MyBioSource) was based on monitoring the release of
fluorescent coumarin from the fluorogenic substrate Ac-WLA-AMC
(Cat #S330, Boston Biochem, Inc.) as described previously21−23 with
minor modifications. Briefly, the activity of recombinant ClpP
proteolytic subunit (1 μg/mL) was measured in assay buffer
composed of 50 mM Tris, 10 mM MgCl2, 100 mM KCl, 1 mM
DTT, 4 mM ATP, 0.02% Triton X-100, and 5% glycerol, pH 8.0
(HCl) using 10 μM of fluorogenic Ac-WLA-AMC substrate as
described.23,24 Two different protocols were used to investigate the
effects of ONC201 and the TR compounds on ClpP activity. Using
the first protocol (Protocol #1), the reaction was initiated instantly by
direct mixing of ClpP enzyme and substrate in the presence of
indicated concentrations of compounds. Applying a second protocol
(Protocol #2), the enzyme and compounds were mixed and incubated
in assay buffer for 60 min before initiating the reaction by adding Ac-
WLA-AMC substrate. The kinetics of the free coumarin fluorescence
was monitored using black, μ-CLEAR 96-well flat bottom plates (Cat
# 655090, Greiner), and the fluorescence of released coumarin was
recorded at 350 nm excitation and 460 nm emission using BMR
PHERAstar plate reader equipped with appropriate FI module (BMG
LABTECH). The slope of the linear portion of the fluorescence signal
over time used as a measure of the activity of ClpP. Measurements
were carried out in triplicate and presented as the rate of fluorescence
change at given concentrations of ClpP and substrate in the presence
or absence of ONC201 or the TR compounds. Dose-dependence of
ClpP activation with different compounds was used for determination
of EC50 for each compound, and the activity of samples treated with
DMSO (vehicle) measured as background and subtracted from
experimental data and the activity of ClpP expressed as RFU/μg of
ClpP/h.
To measure ClpP protease activity in vitro, assays were conducted
using Protocol #2 as described above. Recombinant ClpP was
preincubated for 1 h at 37 °C with DMSO or the indicated
compounds in assay buffer and then an additional h at 37 °C in the
presence of substrate. The reaction volume was 50 μL with a final
concentration of 10 ng/μL ClpP, 5 μM α-casein, and 1% DMSO.
Samples were boiled in SDS sample buffer, resolved by 12% SDS-
PAGE, and silver stained.20
Metabolic Labeling of Nascent Proteins. Nascent proteins
were metabolically labeled and quantified as described previously.25,26
Briefly, cells were incubated in methionine- and cysteine-free medium
(Sigma) containing relevant concentrations of compounds tested for
15 min. 35S-labeled methionine and cysteine (125 μCi; PerkinElmer
EasyTag Express Labeling Mix) were added and allowed to
incorporate for 30 min. Cells were then washed twice in ice-cold
PBS, scraped, and collected by centrifugation. Cell pellets were lysed
in RIPA medium containing protease inhibitors (Roche), and protein
concentrations were determined by the Bradford assay (Amresco).
Trichloroacetic acid (TCA) was added to a final concentration of
20%, and precipitated proteins were captured on glass microfiber
filters by filtration under vacuum. The filters were washed twice with
20% TCA and once with 100% ethanol and allowed to air-dry. The
filters were then transferred to vials containing scintillation fluid
(EcoScint), and radioactivity was quantified using a scintillation
counter. The amount of radioactivity was normalized to the protein
concentration for each sample.
■ RESULTS AND DISCUSSION
ONC201 Analogues are Highly Potent Inhibitors of
TNBC Growth. Madera Therapeutics synthesized a number of
novel chemical analogues of ONC201 known as the TR
compounds. TR-31, first published by Nanjing Gator
Meditech, is identical to ONC212.11,16−18 TR-42, TR-65,
and TR-57 were designed to address limitations of ONC201,
including modest cell activity and dose-dependent pharmaco-
kinetics. Madera also synthesized additional amine-containing
analogues (TR-79, TR-80, and TR-81) for the purpose of
creating affinity ligands to capture TR binding proteins (Figure
1a).
Figure 1. ONC201 and TR analogues inhibit cell growth and induce ATF4 and CHOP activation. (a) Chemical structures of ONC201 and TR
compounds. (b) Cell viability of ONC201 and TR compounds using MTS assay in SUM159 cells. IC50 values are shown in the table at left (a).
Data shown as mean ± SEM, representative of N = 4 replicates. (c) Growth of SUM159 cells determined by crystal violet assay, representative of N
= 3 replicates. (d) Changes in cell number determined by Hoechst stain, representative of N = 2 replicates. (e) Immunoblots of SUM159 lysates for
ATF4, CHOP, and β-actin.
We compared ONC201 and the TR compounds for effects
on growth inhibition of two established models of TNBC
(MDA-MB-231, SUM159 cells). Cells were incubated with
ONC201 or the TR compounds for 24−72 h, and cell viability
was measured using MTS assay. The TR compounds were all
significantly more potent compared to ONC201, with IC50
values ∼100-fold lower than ONC201 in these cells (Figure
1b). Growth inhibition was confirmed by crystal violet colony
formation assays (Figure 1c) and cell counting experiments
(Figure 1d).
ONC201 and analogues have been shown to induce an ISR
in multiple cancer cell lines.1,7,9,27 CHOP and ATF4 proteins
are common markers of the ISR response and ER stress,28 and
we compared the ability of ONC201 and the TR compounds
to induce CHOP and ATF4. Incubation of SUM159 or MDA-
MB-231 cells with ONC201 or TR-57 strongly induced dose-
and time-dependent increases in ATF4 as measured by
immunoblotting. The amount of ONC201 or TR-57 required
to increase ATF4 closely reflected the IC50 values for growth
inhibition in these cells. While the effects on CHOP were more
modest and peaked earlier than ATF4 (Figure 1e), these data
confirmed the activation of the ISR by these compounds.
Under the same conditions, we observed increased Erk and Akt
phosphorylation (Figure S1).
ONC201 was shown to increase PARP cleavage and
apoptosis in some cancer models2,29 but not others.7 We
tested the effects of ONC201 and select TR analogues on
caspase activity in SUM159 cells using a fluorogenic Ac-
DEVD-AMC substrate. No significant increase in caspase
activity was detected by either fluorogenic assays or
immunoblotting for PARP cleavage, even at the highest
concentrations of ONC201 or TR-57 tested. By contrast,
staurosporine, an established apoptosis inducer, increased Ac-
DEVD-AMC cleavage as expected (Figure S1). Cell counting
experiments confirmed that these compounds did not reduce
the total number of cells below the initial value, even after 72 h
incubation (Figure 1d). Thus, these compounds, at the
concentrations tested, are having cytostatic effects but not
increasing caspase-dependent cell death in SUM159 cells.
Affinity Chromatography Identifies the Mitochon-
drial Protease ClpP as a Target of ONC201 and the TR
Compounds. To identify protein targets of ONC201, we
coupled modified ONC201 analogues (TR-79, TR-80, and
TR-81 (Figure 1a)) to agarose beads. Addition of the spacer
arm and primary amine did not significantly reduce the
potency of TR-79 to inhibit TNBC growth (Figure 1b). To
control for nonspecific interactions, we compared our TR-80
affinity column protein binding results to agarose alone or
Figure 2. Identification of ClpP as an ONC201 and TR compound binding protein. (a) HeLa cell lysate was mixed with the indicated beads in the
absence or presence of free TR-80. A silver stained gel is shown, and the band indicated by the arrow was excised and subjected to mass
spectrometry for identification. (b) Replicate samples from panel a were immunoblotted with ClpP antibodies. (c, d) TR-81 beads were charged
with HeLa cell lysate and eluted with 50 μM TR-57. A portion of the eluant was silver stained (c) or immunoblotted (d) for ClpP. (e) Pure,
recombinant human ClpP was mixed with the indicated beads in the absence or presence of 50 μM TR-57 and immunoblotted for ClpP. (f, g)
HeLa cell lysates were mixed with TR-81 beads in the presence of the indicated compounds and immunoblotted for ClpP. (h) HeLa cells were
treated with the indicated compounds for 30 min, and lysates were mixed with TR-81 beads and immunoblotted for ClpP.
agarose coupled to an unrelated drug, PQ. HeLa cell lysates
were mixed with control beads, PQ-beads, or TR-80 beads in
the absence or presence of excess free TR-80. Following
incubation of beads with lysate, the beads were washed and
boiled in sample buffer to release bound proteins, and the
samples were resolved by SDS-PAGE and silver stained. A
distinct protein band of ∼24 kDa was observed that did not
bind the control beads or the PQ-beads and only bound TR-80
beads in the absence of free TR-80. The protein, indicated by
the arrow (Figure 2a), was excised, trypsin digested, and
subjected to MALDI TOF/TOF mass spectrometry. MAS-
COT analysis identified this protein as the human mitochon-
drial protease, ClpP (Methods and Table S1).
To confirm the mass spectrometry results, the experiment
was repeated as above except the samples were immunoblotted
with anti-ClpP antibodies. ClpP was only detected bound to
TR-80 beads in the absence of free TR-80 (Figure 2b).
Because total cell lysate was applied to TR-81 beads, we sought
to determine if ClpP binding to TR-81 was direct or mediated
by other proteins. To this end, TR-81 beads were charged with
HeLa cell lysates, washed to remove nonspecific proteins, and
eluted with 50 μM free TR-57. The eluant was resolved by
SDS-PAGE and silver stained or immunoblotted with ClpP
antibodies. A single protein band at 24 kDa was observed upon
silver staining of the eluate (Figure 2c), and immunoblotting
confirmed the protein to be ClpP (Figure 2d). Because ClpP
was the only protein detected in the eluate (Figure 2c), it
suggests that ClpP binds directly to TR-81 and also that TR-81
is highly specific for ClpP. Confirmation of direct binding
between TR-81 and ClpP was shown by incubation of pure
recombinant human ClpP with TR-81 beads (Figure 2e).
To compare the relative ability of ONC201 or TR
compounds to bind ClpP in vitro, we used TR-81 beads in a
competition assay. Increasing concentrations of ONC201, TR-
31 (ONC212),11 or TR-57 were mixed with HeLa cell lysates
or added directly to HeLa cells in culture. These lysates were
Figure 3. Activation of ClpP by ONC201 and the TR compounds. (a) Purified, recombinant human ClpP was incubated with the indicated
concentrations of each compound, and ClpP peptidase activity was measured. (b) Recombinant human ClpP was preincubated for 1 h at 37 °C
with the indicated compounds and then for an additional hour at 37 °C in the presence of casein. Reaction products were resolved by SDS-PAGE
and silver stained.
applied to TR-81 beads and the amount of ClpP bound
assessed by immunoblotting. ONC201, TR-57, and TR-31 all
reduced ClpP binding to TR-81 beads in a dose-dependent
manner whether mixed with HeLa cell lysates (Figure 2f,g) or
added to cell culture media (Figure 2h). Importantly, both TR-
57 and TR-31 exhibited a ∼10-fold greater potency over
ONC201 in reducing ClpP binding whether applied to cell
lysates or cell cultures. To determine if TR-81 bound ClpP
from other cancer cell lines, we generated cell lysates from
breast cancer (SUM159, MCF7), lung (A549), prostate
(PC3), or pancreatic (PANC1) cells and performed similar
experiments. ClpP bound immobilized TR-81 from all cell
lines tested, and this binding could be prevented with TR-57
(Figure S2), indicating that the interaction between TR
compounds and ClpP was not restricted to HeLa cells but was
observed from multiple different cancer cell types.
ONC201 and TR Compounds Activate ClpP Peptidase
and Protease Activity. We next tested the effects of these
compounds on ClpP enzymatic activity. Using purified,
recombinant human ClpP protein and a select ClpP peptide
fluorogenic substrate (Ac-WLA-AMC), we measured the
peptidase activity of ClpP in the presence or absence of
ONC201 and TR compounds. As shown in Figure 3a,
incubation of ClpP with ONC201 or TR-57 strongly increased
ClpP peptidase activity in a dose- and time-dependent manner.
We then compared the effects of other TR compounds on
ClpP activity. TR-27, 65, 66, and 79 all activated ClpP in a
dose-dependent manner similarly to that observed with TR-57
and ONC201. All of the TR compounds were observed to be
more potent activators of ClpP than ONC201. We also tested
the effects of the recently reported ClpP activator D9.30 D9
also increased ClpP activity albeit at much higher concen-
trations (EC50 ∼ 110 μM), compared to that observed for
ONC201 or the TR compounds (Figure S4).
ONC201 and TR-57 were tested for their effects on ClpP
protease activity. We preincubated recombinant ClpP with
DMSO, ONC201, or TR-57 and then assayed for casein
proteolysis. ONC201 and TR-57 increased ClpP activity
toward casein proteolysis with an observed half maximal dose
of ∼1.25 μM and ∼200 nM for ONC201 and TR-57,
respectively (Figure 3b). These results demonstrate that
ONC201 and the TR compounds increase ClpP activity
toward unstructured proteins (casein) and peptide substrates.
ClpP Knockdown Reduces the Effects of ONC201 and
TR-57 on the ISR and Cell Growth. To investigate if ClpP
was a biological target for ONC201 and the TR compounds,
siRNA knockdown of ClpP was performed in SUM159 cells.
ClpP knockdown was verified by immunoblotting, and ClpP
expression was almost completely eliminated by this treatment
(Figure 4a). Next, the effect of ClpP knockdown on CHOP/
ATF4 induction by ONC201 and TR-57 was examined.
Incubation of WT SUM159 cells with ONC201 or TR-57,
increased the amount of CHOP protein after 24 h. By contrast,
no increase in CHOP was observed after ONC201/TR-57
treatment of the ClpP knockdown cells (Figure 4a). Similar
results were observed with ATF4 (Figure S3).
The mitochondrial transcription factor A (TFAM) was
recently shown to be reduced by ONC201 treatment.7 From a
global proteomics analysis, we observed that the mitochondrial
protein elongation factor Tu (TUFM) and other mitochon-
Figure 4. Effects of ONC201 and TR-57 are prevented by ClpP knockdown in SUM159 cells. (a) Immunoblot of lysates from SUM159 cells
transfected with a nontargeting siRNA (siCTRL) or siRNA targeting ClpP (siClpP) and treated with either 10 μM ONC201, 150 nM TR-57, or
DMSO for 24 h. Blots shown are representative of three biological replicates. (b) Total protein synthesis measured in SUM159 cells transfected
with siCTRL or siClpP after treatment with ONC201, TR-57, cycloheximide, or DMSO. (c) Cell viability plots for SUM159 cells transfected with
siCTRL (black circles) or siClpP (white squares) using Hoechst stain for total cell count after 48-h treatment with ONC201 or TR-57. Graphs
shown in (b) and (c) are representative of 2 biological replicates. Error bars represent standard error of the mean (SEM) from replicates.
drial proteins were strongly reduced by ONC201 and TR-57
treatment of SUM159 cells (E.M.J. Fennell, unpublished
observations). The effects of ONC201 and TR-57 on the
reduction of TFAM and TUFM were compared by
immunoblotting control or ClpP knockdown cells. Interest-
ingly, the ONC201/TR-57-stimulated reduction of these
proteins was prevented in the ClpP knockdown cells (Figure
4a). Moreover, the less potent ClpP activator D9, also
decreased TFAM and TUFM in a ClpP-dependent manner
(Figure S3).
ONC201 has been shown to activate the protein synthesis
inhibitory eIF2a kinases.27 Using 35S-methionine incorporation
into proteins,25,26 we measured the effects of ONC201 and
TR-57 on protein synthesis in SUM159 cells. Both compounds
significantly inhibited total protein synthesis (>50%) after 24 h
(Figure 4b) with TR-57 much more potent than ONC201.
Knockdown of ClpP strongly inhibited this response,
consistent with activation of ClpP being required. Thus,
these results support the importance of ClpP activation by
ONC201 or TR-57 as essential for the inhibition of protein
synthesis by these compounds.
Lastly, the effects of ClpP knockdown on growth inhibition
by ONC201 and TR-57 were examined. ClpP knockdown cells
were incubated with or without ONC201 or TR-57, and cell
proliferation was measured. The results of these studies
demonstrated that the growth inhibitory effects of ONC201
or TR-57 were significantly reduced in the ClpP knockdown
cells as compared to WT cells. Thus, these studies demonstrate
that the cytostatic effects of ONC201 and TR-57 are in part
dependent on ClpP, providing further evidence that this
protein is an important target for these compounds (Figure
4c).
In conclusion, the rapid clinical advance of ONC201 has
preceded a detailed understanding of the molecular mechanism
of drug action.3 We now demonstrate that highly potent
chemical agents related to ONC201 may be prepared and that
the mitochondrial protein ClpP is a novel target for ONC201
and the related TR compounds. Our data provide evidence for
direct binding and activation of the peptide and protease
activity of ClpP. Furthermore, through knockdown experi-
ments, we demonstrate that ClpP is essential for the activation
of the ISR and subsequent events, including protein synthesis
inhibition and ultimately mitochondrial changes initiated by
these compounds (Figure 5).
While multiple mechanisms of ONC201 action have been
proposed, our results support the importance of ClpP
activation to the ISR and subsequent mitochondrial events.
This includes ClpP-dependent reduction of the mitochondrial
proteins TFAM and TUFM in cells treated with ONC201 or
the TR compounds. In this way, our findings are in agreement
with Greer et al., who identified reduced TFAM and
mitochondrial metabolism as part of the ONC201 response.
Interestingly, they observed TFAM protein levels decreased
prior to a change in RNA levels.7 Our data showing inhibition
of protein synthesis by ONC201 and TR-57, in a ClpP-
dependent manner, further supports this observation (Figure
4).
The ATP-dependent CLP protease (ClpP) is a highly
conserved serine protease found in species ranging from
bacteria to humans.31−33 In humans, ClpP is localized to the
mitochondrial matrix and is important for regulating responses
to cell stresses, including heat shock, nutrient deprivation, and
other cellular insults.34,35 ClpP has been linked to the
mitochondrial unfolded protein response (UPR), where it is
involved in the regulation of protein homeostasis.36 ClpP is
overexpressed in some leukemias, and human ClpP has
recently been recognized as a potential target for cancer
chemotherapy.37,38 Activators of ClpP, including the acyldep-
sipeptides (ADEPs) and other compounds, are currently being
investigated as novel anticancer or antimicrobial treat-
ments.30,38,39
The mechanism of ClpP activation by ONC201 and TR
compounds remains to be established. In cells, the ClpP
complex is composed of two components, the ATP-binding
chaperone protein (ClpX) and the barrel-shaped ClpP
peptidase.40 Other known activators of human and bacterial
ClpP (i.e., ADEPs) are believed to displace ClpX and open the
central substrate cavity. Elegant structural studies demon-
strated that opening this cavity may increase the peptidase
activity of ClpP independently of the protein unfolding activity
of ClpX.41 Wong and demonstrated that the ADEPs bound to
a hydrophobic cleft between the monomers in the heptamer
structure of purified ClpP.39
Our data are consistent with the effects of ONC201 and the
TR compounds being mediated through direct binding to
ClpP. This thesis is supported by affinity column binding
assays and biochemical assays where we used isolated, purified
ClpP in the absence of ClpX to assess the effects on enzyme
activity. While we only tested activity on peptides and a protein
lacking significant structure (casein), the effects on intact
proteins remains to be determined. However, our proteomics
analysis after ONC201 or TR-57 treatment indicates a
significant reduction in multiple mitochondrial proteins,
suggesting that ClpP activation in cells is leading to the
degradation of intact mitochondrial proteins (E.M.J. Fennell,
unpublished observations).
In all studies, we observed that the TR compounds were
more potent binders and activators of ClpP than ONC201 or
the recently reported compound D9. While we were unable to
Figure 5. Model for the regulation of ClpP and the ISR by ONC201
and the TR compounds. ClpP, a mitochondrial protease, is activated
by ONC201 and TR analogues to degrade mitochondrial proteins.
Protein fragments are exported from the mitochondria and activate
the unfolded protein response (ATF4, CHOP), decrease TFAM
activity, and inhibit protein synthesis. ClpP-mediated changes in
ATF4, CHOP, and TFAM lead to alterations in metabolism.
prevent binding of ClpP to TR-81 beads with ADEP or D9
(Figure S2), whether or not ONC201 or the TR compounds
bind to the same pocket as these compounds or compete with
ClpX binding in intact cells remains to be determined.
Importantly, the potent effects of the TR compounds on
ClpP directly paralleled the effects of these compound on ISR
induction, protein synthesis, and growth inhibition.
The mechanisms by which ONC201 and the TR
compounds inhibit cell growth or induce cell death also
remains to be determined. The ADEPs affect mitochondrial
morphology and inhibit oxidative phosphorylation after
extended exposure. We confirmed that ONC201 and the TR
compounds induce changes in mitochondrial morphology,
inhibition of oxidative phosphorylation, and increased lactic
acid formation as reported by others (E. Holmuhamedov,
unpublished observations). While we observed primarily
cytostatic responses in our studies, these results may be cell
type-dependent, as others have observed apoptotic responses.
We also did not observe a complete elimination of the
cytostatic effects of these compounds in ClpP knockdown cells,
suggesting that additional mechanisms of action may also
contribute to the growth inhibitory effects of these
compounds.
In summary, ONC201 as an unoptimized screening hit has
displayed remarkable clinical activity in a range of difficult-to-
treat cancers. We propose that the clinical response observed
by treatment with ONC201 underscores the importance of a
common biological mechanism of action that explains its broad
efficacy against multiple cancer types. Our studies demonstrate
that ClpP is the common target for both ONC201 and the TR
compounds, and activation of ClpP results in modulation of
the integrated stress response pathway. Thus, the TR
compounds, based on the pioneering work of Janda and
colleagues,14 are novel and highly potent activators of ClpP
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